Sugi Predict

Sugi Predict / Compounds / SCHEMBL751617

SCHEMBL751617

SCHEMBL751617

CCOC(=O)c1ccc(N)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.54
▸ MAOA P21397 2/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ HSD17B10 Q99714 4/20 0.51
▸ ALDH1A1 P00352 4/20 0.51
▸ GAA P10253 5/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ ALOX15 P16050 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ CA12 O43570 2/20 0.50
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ CA7 P43166 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ CA14 Q9ULX7 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31621322 0.91 DGAT1 (0.50) LMNAMAOACYP1A2CYP3A4HSD17B10
SCHEMBL1496445 0.87 LMNA (0.54) LMNAMAOACYP1A2CYP3A4HSD17B10
SCHEMBL8490256 0.84 TSHR (0.59) LMNAMAOACYP1A2CYP3A4HSD17B10
SCHEMBL2888716 0.84 TSHR (0.60) LMNAMAOACYP1A2CYP3A4HSD17B10
SCHEMBL367075 0.83 TSHR (0.57) ALDH1A1GAASMN1; SMN2MEN1KMT2A
SCHEMBL29375324 0.83 ALDH1A1 (0.64) LMNAMAOACYP1A2CYP3A4HSD17B10
SCHEMBL7222675 0.83 TSHR (0.53) LMNACYP1A2HSD17B10ALDH1A1GAA
SCHEMBL754826 0.83 LMNA (0.62) LMNAMAOACYP1A2CYP3A4HSD17B10
SCHEMBL2132644 0.83 ALDH1A1 (0.64) LMNAMAOACYP1A2CYP3A4HSD17B10
SCHEMBL22924372 0.81 NPC1 (0.55) LMNACYP1A2HSD17B10ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230139-A1 Novel Process and Intermediate for the Preparation of Apalutamide BDR LIFESCIENCES PRIVATE LIMITED (IN) 2025-07-17 — — US claimed
CN-118955313-B Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2025-06-17 — — CN claimed
EP-4504715-A1 NOVEL PROCESS AND INTERMEDIATE FOR THE PREPARATION OF APALUTAMIDE BDR Lifesciences Private Limited (IN) 2025-02-12 — — EP claimed
CN-119301108-A New process and intermediates for the preparation of apaluramine BDR生命科学私人有限公司 2025-01-10 — — CN claimed
CN-118955313-A Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2024-11-15 — — CN claimed
WO-2023195026-A1 NOVEL PROCESS AND INTERMEDIATE FOR THE PREPARATION OF APALUTAMIDE BDR LIFESCIENCES PRIVATE LIMITED (IN) 2023-10-12 — — WO claimed
CN-108947782-A A kind of bromine fluorine Multi substituted benzenes formaldehyde derivatives and preparation method 上海罕道医药科技有限公司 2018-12-07 — — CN claimed
WO-2026031298-A1 METHOD FOR SYNTHESIZING KEY INTERMEDIATE OF ENZALUTAMIDE 安徽峆一药业股份有限公司 2026-02-12 — — WO disclosed
US-12492177-B2 RAR-α compounds for inflammatory disease and male contraception Orphagen Pharmaceuticals, Inc. (US) 2025-12-09 — — US disclosed
US-20250230139-A1 Novel Process and Intermediate for the Preparation of Apalutamide BDR LIFESCIENCES PRIVATE LIMITED (IN) 2025-07-17 — — US disclosed
CN-118955313-B Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2025-06-17 — — CN disclosed
CN-118955313-B Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2025-06-17 — — CN disclosed
EP-4504715-A1 NOVEL PROCESS AND INTERMEDIATE FOR THE PREPARATION OF APALUTAMIDE BDR Lifesciences Private Limited (IN) 2025-02-12 — — EP disclosed
WO-1997009297-A2 SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES VISION PHARMACEUTICALS L.P. (US) 1997-03-13 — — WO disclosed
EP-0728018-A1 THERAPY THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-28 — — EP disclosed
EP-0661259-A1 Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity BRISTOL-MYERS SQUIBB COMPANY (US) 1995-07-05 — — EP disclosed
WO-1995013095-A2 THERAPY THE WELLCOME FOUNDATION LIMITED (GB) 1995-05-18 — — WO disclosed
US-4333940-A Ring-fluorinated 4-(monosubstituted-amino) phenyl compounds in inhibiting atherosclerotic lesion development AMERICAN CYANAMID COMPANY (US) 1982-06-08 — — US disclosed
US-4243609-A ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1981-01-06 — — US disclosed
EP-0003663-A2 Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them AMERICAN CYANAMID COMPANY (US) 1979-08-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230139-A1 Novel Process and Intermediate for the Preparation of Apalutamide PDE8B, PDE8A, PGA5 LMNA 2162/4885MAOA 722/4885CYP1A2 545/4885
US-12492177-B2 RAR-α compounds for inflammatory disease and male contraception RARA, RARB, RARG LMNA 1653/4885MAOA 3115/4885CYP1A2 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.